Bismuth-Amoxicillin-Vonoprazan Triple, Amoxicillin-Vonoprazan Dual, and Clarithromycin-Based Triple Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Open-Label, Randomized Trial.

Hsu PI, Sheu MJ, Chen CL, Lei WY, Shih CA, Tsay FW, Kao SS, Shie CB, Wu PJ, Kuo CH, Yang JC, Chen KY, Chuah SK, Lee CL, Lee HC, Tai WC, Tsai TJ, Kao JY, Wu DC, Taiwan Acid‐related Disease & Microbiota (TARD‐M) Consortium

Open source

DOI: 10.1111/hel.70131
Published: 2026 Jul-Aug
Container: Helicobacter
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/hel.70131,
  title = {Bismuth-Amoxicillin-Vonoprazan Triple, Amoxicillin-Vonoprazan Dual, and Clarithromycin-Based Triple Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Open-Label, Randomized Trial.},
  author = {Hsu PI and Sheu MJ and Chen CL and Lei WY and Shih CA and Tsay FW and Kao SS and Shie CB and Wu PJ and Kuo CH and Yang JC and Chen KY and Chuah SK and Lee CL and Lee HC and Tai WC and Tsai TJ and Kao JY and Wu DC and Taiwan Acid‐related Disease \& Microbiota (TARD‐M) Consortium},
  year = {2026},
  journal = {Helicobacter},
  doi = {10.1111/hel.70131},
  url = {https://doi.org/10.1111/hel.70131}
}

RIS

TY  - JOUR
TI  - Bismuth-Amoxicillin-Vonoprazan Triple, Amoxicillin-Vonoprazan Dual, and Clarithromycin-Based Triple Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Open-Label, Randomized Trial.
AU  - Hsu PI
AU  - Sheu MJ
AU  - Chen CL
AU  - Lei WY
AU  - Shih CA
AU  - Tsay FW
AU  - Kao SS
AU  - Shie CB
AU  - Wu PJ
AU  - Kuo CH
AU  - Yang JC
AU  - Chen KY
AU  - Chuah SK
AU  - Lee CL
AU  - Lee HC
AU  - Tai WC
AU  - Tsai TJ
AU  - Kao JY
AU  - Wu DC
AU  - Taiwan Acid‐related Disease & Microbiota (TARD‐M) Consortium
PY  - 2026
JO  - Helicobacter
DO  - 10.1111/hel.70131
UR  - https://doi.org/10.1111/hel.70131
ER  -

APA

PI, H., MJ, S., CL, C., WY, L., CA, S., FW, T., SS, K., CB, S., PJ, W., CH, K., JC, Y., KY, C., SK, C., CL, L., HC, L., WC, T., TJ, T., JY, K., DC, W., & Consortium, T. A. D. &. M. (. (2026). Bismuth-Amoxicillin-Vonoprazan Triple, Amoxicillin-Vonoprazan Dual, and Clarithromycin-Based Triple Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Open-Label, Randomized Trial.. Helicobacter. https://doi.org/10.1111/hel.70131

Source records

pubmed · retrieved 2026-09-26T14:54:29.107Z